Sharda Cropchem FY26 PAT Doubles to ₹681 Cr, Revenue Up 22% to ₹5,268 Cr
Sharda Cropchem reported FY26 consolidated revenue of ₹5,268 Cr, up 22% YoY. PAT more than doubled to ₹681 Cr (+124% YoY). EBITDA grew 69% to ₹1,040 Cr with margins at 19.7%. The company achieved its highest RoCE of 30.4%. A final dividend of ₹9 per share was recommended, totaling ₹15 for FY26.
The announcement details substantial financial growth, including a doubling of PAT and significant revenue increases, which are material to investors and the company's valuation.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT, along with a record RoCE and a recommended dividend, indicating strong financial performance and positive outlook.
Sharda Cropchem Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a significant year-on-year growth across key financial metrics.
For the full financial year FY26, consolidated revenue stood at ₹5,268 crore, an increase of 22% compared to ₹4,320 crore in FY25. EBITDA grew by 69% to ₹1,040 crore from ₹613 crore in the previous year, with margins expanding to 19.7% from 14.2%. Profit After Tax (PAT) more than doubled, surging by 124% to ₹681 crore in FY26, up from ₹304 crore in FY25. Earnings Per Share (EPS) for FY26 was ₹75.47, a substantial increase from ₹33.74 in FY25. The company also achieved its highest-ever Return on Capital Employed (RoCE) of 30.4% for FY26.
The agrochemical segment contributed 90% to the revenue, with overall volumes increasing by 13.4% year-on-year in FY26. The company's product registrations stand at 3,011, with 1,004 applications pending. Sharda Cropchem maintained a debt-free status, holding ₹702 crore in cash, bank, and liquid investments as of March 31, 2026.
For the fourth quarter of FY26 (Q4 FY26), revenue grew by 13% to ₹2,065 crore from ₹1,829 crore in Q4 FY25. EBITDA for the quarter increased by 75% to ₹513 crore from ₹293 crore, and PAT rose by 57% to ₹319 crore from ₹204 crore. The Board of Directors has recommended a final dividend of ₹9 per equity share, which, combined with the interim dividend of ₹6 paid in December 2025, brings the total dividend for FY26 to ₹15 per share.
What to do with a filing like this
Sharda Cropchem Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sharda Cropchem Limited. Read the original for the full detail.